Updates in the Management of Extensive-Stage Small Cell Lung Cancer

An overview of the prevalence and prognosis of small cell lung cancer.

Mark Socinski, MD, of AdventHealth Cancer Institute discusses his approach to treating small cell lung cancer and reacts to advances in the treatment of extensive-stage disease.

A review of current options for management of SCLC and the challenges of treating this population.

The rationale for adding an immunotherapy agent to frontline therapy for extensive-stage small cell lung cancer and considerations for patient selection.

Dr Mark Socinski reviews the IMpower133 trial of first-line chemotherapy plus atezolizumab in extensive-stage small cell lung cancer.

Practical implications of the IMpower133 study for providers and patients.

Benjamin Levy, MD, of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, comments on risk factors and the prognosis for patients diagnosed with small cell lung cancer.

Dr Benjamin Levy describes common treatment approaches for patients with limited-stage small cell lung cancer and extensive-stage small cell lung cancer.

An overview of current gaps in treatment for patients with extensive-stage, or metastatic small cell lung cancer.

A discussion regarding typical response rates to frontline therapy for extensive-stage small cell lung cancer and considerations for incorporating an immunotherapy agent into first-line treatment.

A review of safety and efficacy data demonstrated by the IMpower133 clinical trial of atezolizumab plus chemotherapy as first-line treatment for extensive-stage small cell lung cancer.

Dr Benjamin Levy describes how the results of the IMpower133 trial and subsequent FDA approval will impact clinical practice and the outlook for patients with extensive-stage small cell lung cancer.